Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregor Novak

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Medicina (Kaunas, Lithuania)|February 24, 2024
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel DiseaseŠpela Pintar, Jurij Hanžel, David Drobne, et al.
Drugs|March 2, 2017
Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
European Journal of Gastroenterology & Hepatology|March 26, 2023
Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitisGregor Novak, Nejc Sever, Jurij Hanžel, et al.
Drugs|February 25, 2017
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
Inflammatory Bowel Diseases|March 30, 2021
Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort StudyVincent Joustra, Marjolijn Duijvestein, Aart Mookhoek, et al.
Journal of Crohn'S & Colitis|September 30, 2017
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2019
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel diseaseDavid Drobne, Tina Kurent, Saša Golob, et al.
European Journal of Gastroenterology & Hepatology|August 17, 2021
Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's diseaseJurij Hanžel, Matic Koželj, Ana Špes Hlastec, et al.
The Cochrane Database of Systematic Reviews|July 22, 2017
Histologic scoring indices for evaluation of disease activity in Crohn's diseaseGregor Novak, Claire E Parker, Rish K Pai, et al.
United European Gastroenterology Journal|July 19, 2019
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel diseaseJurij Hanžel, Nejc Sever, Ivan Ferkolj, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Medicina (Kaunas, Lithuania)|February 24, 2024
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel DiseaseŠpela Pintar, Jurij Hanžel, David Drobne, et al.
Drugs|March 2, 2017
Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
European Journal of Gastroenterology & Hepatology|March 26, 2023
Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitisGregor Novak, Nejc Sever, Jurij Hanžel, et al.
Drugs|February 25, 2017
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
Inflammatory Bowel Diseases|March 30, 2021
Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort StudyVincent Joustra, Marjolijn Duijvestein, Aart Mookhoek, et al.
Journal of Crohn'S & Colitis|September 30, 2017
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2019
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel diseaseDavid Drobne, Tina Kurent, Saša Golob, et al.
European Journal of Gastroenterology & Hepatology|August 17, 2021
Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's diseaseJurij Hanžel, Matic Koželj, Ana Špes Hlastec, et al.
The Cochrane Database of Systematic Reviews|July 22, 2017
Histologic scoring indices for evaluation of disease activity in Crohn's diseaseGregor Novak, Claire E Parker, Rish K Pai, et al.
United European Gastroenterology Journal|July 19, 2019
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel diseaseJurij Hanžel, Nejc Sever, Ivan Ferkolj, et al.
Pageof 3